X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Eisai divested its rights for vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.
Lead Product(s): Betahistine Dimesilate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Merislon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 29, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
